About this trial
The goal of this clinical trial is to compare eradication rates of Helicobacter pylori in patients aged 18-70 years with first infection. The main questions it aims to answer are:
* Main indicators: the eradication rate of Helicobacter pylori for eradication. * Secondary indicators: symptomatic relief rate at 2 weeks after treatment and 4 weeks after the end of treatment; compliance and adverse reactions during treatment.
Eligibility criteria
Qualifiers
Age 18-70 years, regardless of sex; chronic gastritis, peptic ulcer or dyspeptic symptoms, clear Hp infection (positive 13C-urea breath test); voluntary Hp eradication treatment; women of childbearing age are required to use a medically desirable form of contraception during the trial and for 1 month after the trial.
Disqualifiers
Have contraindications to the study drug or are allergic to the study drug; have taken a PPI within 2 weeks and an antibiotic or bismuth within 4 weeks; pregnant and lactating women; and Have undergone upper gastrointestinal surgery; refluse to sign the informed consent document.
Trial design
Treatments tested in this trial
- Rabeprazloe+bismuth+amoxicillin+clarithromycin
- Vonoprazan+amoxicillin+clarithromycin 14 days
- Vonoprazan+amoxicillin+clarithromycin 7 days
- Vonoprazan+tetracycline+furazolidone 14 days
- Vonoprazan+tetracycline+furazolidone 7 days
- Vonoprazan+amoxicillin+furazolidone 7 days
- Vonoprazan+amoxicillin+tetracycline 14 days
- Vonoprazan+amoxicillin 7 days
- Vonoprazan+amoxicillin 14 days
Treatment groups
9
Treatment groupsSee each treatment group below.